{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T21:48:25Z","timestamp":1769896105478,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1136\/ijgc-2019-000973","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T05:56:09Z","timestamp":1587534969000},"page":"1026-1033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-8396","authenticated-orcid":false,"given":"Rosemary","family":"Lord","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Rauniyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamsin","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlaith","family":"Condon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Lofts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind M","family":"Glasspool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-000973_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00132","article-title":"Real-world evidence and randomized studies in the precision oncology era: the right balance","volume":"1","author":"Gyawali","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0015","unstructured":"M Gores , DPatel . RWE: From \u201cNice to have\u201d to \u201cmust have\u201d. Available: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/rwe-from-nice-to-have-to-must-have.pdf?_=1538123742899 [Accessed 28 Sep 2018]."},{"key":"10.1136\/ijgc-2019-000973_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/0284186X.2011.653437","article-title":"Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade","volume":"51","author":"Oberaigner","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0025","unstructured":"NICE . Managing advanced (stage II-IV) ovarian cancer. Available: https:\/\/pathways.nice.org.uk\/pathways\/ovarian-cancer#path=view%3A\/pathways\/ovarian-cancer\/managing-advanced-stage-ii-iv-ovarian-cancer.xml&content=view-node%3Anodes-second-line-and-subsequent-chemotherapy [Accessed 3 Sep 2018]."},{"key":"10.1136\/ijgc-2019-000973_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0035","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000973_bb0040","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0045","doi-asserted-by":"crossref","first-page":"viii57","DOI":"10.1093\/annonc\/mdx442","article-title":"New treatments in ovarian cancer","volume":"28","author":"Pujade-Lauraine","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0050","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0055","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000973_bb0060","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2019-000973_bb0065","unstructured":"eMC . Lynparza 50 mg hard capsules - Summary of Product Characteristics (SmPC). Available: https:\/\/www.medicines.org.uk\/emc\/product\/6821\/smpc [Accessed 20 Dec 2019]."},{"key":"10.1136\/ijgc-2019-000973_bb0070","doi-asserted-by":"crossref","first-page":"viii63","DOI":"10.1093\/annonc\/mdt315","article-title":"BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups","volume":"24 Suppl 8","author":"Safra","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e16519","article-title":"Survival in patients with BRCA mutation-positive platinum-sensitive recurrent ovarian cancer","volume":"32","author":"Hirst","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0080","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2019-000973_bb0085","article-title":"Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer","volume":"35","author":"Friedlander","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0090","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000973_bb0095","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2019-000973_bb0100","unstructured":"O Cavaln , SChilukuri, MEvers, et al . Real-world evidence: from activity to impact in healthcare decision making. Available: https:\/\/www.mckinsey.com\/industries\/pharmaceuticals-and-medical-products\/our-insights\/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making [Accessed 03 Oct 2018]."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24001737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24001737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-000973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:19:53Z","timestamp":1753222793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24001737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1048891X24001737"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-000973","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-000973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}